Jim Cramer on The Mosaic Company (MOS): 'A Real Tough One to Understand'
We recently published a list of . In this article, we are going to take a look at where The Mosaic Company (NYSE:MOS) stands against other stocks that Jim Cramer discusses.
During the episode, Cramer mentioned The Mosaic Company (NYSE:MOS) and said:
'There's no real theme to the other stocks on the list… Then there are two one-offs, Roblox and Mosaic… Here's a real tough one to understand, Mosaic. It's a fertilizer company. Now this one's an oddity. It's entirely possible that people are playing a theme of China food shortages. And that's one, by the way that, I'm not seeing. I think what it really is is farmers are flush, and that means they're capable of buying tons of fertilizer, which doesn't cost that much anyway.'
Mosaic (NYSE:MOS) produces and markets phosphate and potash-based crop nutrients, animal feed ingredients, and industrial products. Additionally, it offers blended fertilizers, biological complements, and related services. On May 20, Cramer recommended not buying the stock as he said:
'This weekend, when I was at Total Wine & More up there in Norwalk, I was shocked. Someone came to me and said, what do you think about Mosaic? I said, well, you know what, I think it's just, it's killer. It's killer. But it is hype, it is just like a parabolic move. If I come in now, I think I am too late…. I'm going to have to say, [don't buy, don't buy] because it's just up too much. It's up too much. I'm sorry.'
Overall, MOS ranks 13th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of MOS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Yahoo
3 hours ago
- Yahoo
Retail Traders Just Sent This AI Health Stock Soaring 60%
Oscar Health (NYSE:OSCR) has exploded nearly 60% this week, adding close to $2 billion in market cap without a single press release or earnings update. The real catalyst? A retail trading frenzy. OSCR became one of the most-mentioned names on r/WallStreetBets, and trading volume followed suitnearly 50 million shares changed hands on Wednesday alone, the second-highest in the company's history. Options activity lit up as well, with call volumes hitting a record 152,414 that day, and another 95,000 contracts moving by Friday morning, nearly triple the norm. Beneath the surge is a company with serious revenue momentumup 48% in 2023 and 57% in 2024. Adjusted earnings per share reached $0.92 in Q1 2025. But Oscar isn't just selling insuranceit's selling a story. Management brands the company as a health-tech platform, powered by AI and run on what it calls a continuous hackathon model. That pitch, familiar to anyone who's followed high-multiple tech names, is likely helping Oscar catch a more generous valuation than traditional insurers. Retail traders appear to be buying into that promise. Another factor? The Kushner connection. Joshua Kushner, vice chairman of Oscar's board and brother to Jared Kushner, has remained a prominent name in business and politics alike. That visibility might be adding an extra layer of speculation to the mix. But for now, the stock's movement is being driven more by momentum than fundamentals. Oscar is just $3 shy of its all-time highand the retail crowd seems determined to carry it the rest of the way. This article first appeared on GuruFocus.
Yahoo
4 hours ago
- Yahoo
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ('AIM' or the 'Company') (NYSE American: AIM) today announced the receipt of a warning notification (the 'Letter') from the NYSE American LLC (the 'NYSE American') stating that the Company is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the 'Company Guide') requiring stockholders' equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders' deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024. The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025, when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025. On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance. The Company's common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol 'AIM'. The Letter in no way has any effect on such trading and does not affect the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@ in to access your portfolio
